TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tonix Pharmaceuticals Holding Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$5.73−0.31 (-5.13%)
Close on Oct 19, 2026
- Market cap
- $95.32M
- P/E (TTM)
- –
- Dividend yield
- –
Tonix Pharmaceuticals Holding Corp. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Zembrace Symtouch [Member] | $9.31M | $8.55M | $6.30M | 71.1% | +9.0% |
| Tosymra [Member] | $2.37M | $1.55M | $1.46M | 18.1% | +53.2% |
| Tonmya [Member] | $1.42M | – | – | 10.8% | – |
By region
From the segment and revenue-disaggregation notes of Tonix Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.